Scholar Rock (SRRK) Director Akkaraju Buys $5.9M of Stock
Key Points
- Srinivas Akkaraju, a Director at Scholar Rock, increased his stake by 29.5%, now holding 625,038 shares after the transaction.
- Scholar Rock closed at $41.49 on the event date, while the stock recently traded around $42.49, about 2.4% higher since then.
- Analysts maintain a strong buy consensus on Scholar Rock, with a mean price target of $70.44, indicating significant upside potential.
Since the trade, $SRRK is up 0.5% to date (from the $41.49 close on Oct 23, 2026).
Get Scholar Rock Holding text alerts
We text you when insiders, Congress, analysts or big funds move on $SRRK.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Scholar Rock Holding Corporation alert may contain errors. Disclosures
On October 23, 2026, Srinivas Akkaraju bought 142,500 shares of Scholar Rock Holding Corporation (SRRK) for about $5.9 million. This purchase was reported in a Form 4 filing with the SEC. Following this trade, Akkaraju's total ownership rose to 625,038 shares, reflecting a 29.53% increase in his stake.
SRRK
Scholar Rock Holding Corporation
Srinivas Akkaraju vs. the S&P 500
Hypothetical returns from Srinivas Akkaraju's disclosed trades, not real profit or advice. How we model this.
What Changed in Akkaraju's Position
Akkaraju's recent purchase increased his holdings to 625,038 shares. The transaction was made at an average price of $41.32 per share, which is below the stock's recent trading price. This move suggests confidence in Scholar Rock's future prospects.
Other Institutional Activity in Scholar Rock
Driehaus Capital Management has trimmed its stake in Scholar Rock, reducing its holdings by 32,644 shares, now owning 1,920,233 shares valued at about $105.6 million. Siren, L.L.C. also decreased its position by 1,250,327 shares, holding 9,575,013 shares worth approximately $406.8 million. Meanwhile, Orbis Allan Gray Ltd increased its holdings by 1,753,517 shares, now owning 5,933,533 shares valued at about $252.1 million. These movements indicate mixed sentiment among institutional investors.
Scholar Rock Holding Corporation Stock Up 1.9%
The stock closed at $41.49 on October 23, 2026, the same day Akkaraju made his purchase. Recently, SRRK traded around $42.49, which is about 2.4% higher since the event date. However, the stock remains below its 50-day moving average of $49.36 and its 200-day average of $48.21.
Recent Earnings
Scholar Rock reported no revenue in its latest earnings report, with a net margin of 0%. The company is set to announce its next earnings on November 10, 2026, which could provide further insight into its financial health and future plans.
Insider Buying and Selling at Scholar Rock Holding Corporation
Before Akkaraju's recent purchase, other directors sold shares on July 1, 2026. Michael Z. Gilman sold 2,544 shares, Kristina M. Burow sold 3,053 shares, Jeffrey S. Flier sold 3,053 shares, and Joshua Reed also sold 3,053 shares. These sales reflect a trend of insider activity as the company navigates its growth strategies.
Analysts Set New Price Targets
On September 15, 2026, multiple analysts maintained their bullish outlook on Scholar Rock. Evercore ISI Group kept an "Outperform" rating with a target of $72.00, while Piper Sandler maintained an "Overweight" rating with a target of $75.00. Jefferies also maintained a "Buy" rating with a target of $65.00. The consensus among analysts is a strong buy, with a mean price target of $70.44, suggesting significant upside potential from the current trading levels.
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company based in Cambridge, MA. It focuses on developing treatments for spinal muscular atrophy and other rare neuromuscular diseases. The company has a proprietary platform that enhances its understanding of growth factor activation, which is crucial for its drug development efforts.
Bottom Line
Investors should keep an eye on Scholar Rock's upcoming earnings report on November 10, 2026, for insights on its performance. With Srinivas Akkaraju's recent purchase and a positive analyst outlook, the company is positioned for potential growth in the coming months.
Related Filing Alerts
Source: Srinivas Akkaraju's Form 4 filing on $SRRK (Oct 23, 2026). Written by software, not financial advice. How we make alerts